Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Central Institute for Medical and Chemical Laboratory Diagnostics, Innsbruck Medical University, Innsbruck, Austria.
Clin Exp Med. 2018 Aug;18(3):325-336. doi: 10.1007/s10238-018-0490-9. Epub 2018 Feb 7.
The effect of direct oral anticoagulants (DOACs) on turbidimetric measurements of plasma clot formation and susceptibility to fibrinolysis may facilitate a comparison between different classes of anticoagulants in plasma samples. We obtained 424 citrate plasma samples from 226 atrial fibrillation patients on anticoagulation and 24 samples without anticoagulation serving as controls. As comparators, we measured the international normalized ratio (INR) for phenprocoumon samples (N = 166), anti-Xa for low molecular weight heparin (LMWH) samples (N = 42), and DOAC levels with mass spectrometry (dabigatran N = 40, rivaroxaban N = 110, apixaban N = 42). Plasma clot formation and lysis were recorded continuously on a photometer after addition of an activation mix (tissue factor 2 pmol/l and tissue plasminogen activator 333 ng/ml). We used linear regression and ANCOVA for correlation analysis. Clot formation lag phase was prolonged in the presence of anticoagulants in a concentration-dependent manner for DOACs (dabigatran Spearman r = 0.74; rivaroxaban r = 0.78; apixaban r = 0.72, all p < 0.0001), INR dependent for phenprocoumon (r = 0.59, p < 0.0001), anti-Xa level dependent in LMWH samples (r = 0.90, p < 0.0001). Maximum rate of clot formation and peak clot turbidity were reduced in the presence of anticoagulants, but correlated only moderately with the comparator measures of anticoagulation. The clot lysis time was inversely correlated with DOAC concentrations in the presence of recombinant thrombomodulin. A direct ex vivo comparison between the effects of different classes of anticoagulants is possible with turbidimetric measurement of plasma clot formation and lysis. Anticoagulation inhibited clot formation in a plasma concentration manner for DOACs, INR dependent for phenprocoumon, and anti-Xa dependent for LMWH. Susceptibility to fibrinolysis increased with increasing DOAC concentrations.
直接口服抗凝剂 (DOACs) 对血浆凝块形成的浊度测量和纤溶敏感性的影响可能有助于比较不同类别抗凝剂在血浆样本中的差异。我们从 226 名接受抗凝治疗的心房颤动患者和 24 名未接受抗凝治疗的患者中获得了 424 份柠檬酸盐血浆样本作为对照。作为比较,我们测量了苯丙香豆素样本的国际标准化比值(INR)(N=166)、低分子肝素(LMWH)样本的抗 Xa(N=42)和质谱法测量的 DOAC 水平(达比加群 N=40,利伐沙班 N=110,阿哌沙班 N=42)。在加入激活混合物(组织因子 2 pmol/l 和组织纤溶酶原激活物 333 ng/ml)后,我们使用光度计连续记录血浆凝块形成和溶解。我们使用线性回归和协方差分析进行相关性分析。DOAC 的存在以浓度依赖的方式延长了凝血酶原形成的迟滞期(达比加群的 Spearman r=0.74;利伐沙班 r=0.78;阿哌沙班 r=0.72,均 p<0.0001),依赖于 INR 的苯丙香豆素(r=0.59,p<0.0001),依赖于 LMWH 样本的抗 Xa 水平(r=0.90,p<0.0001)。在抗凝剂存在的情况下,最大凝块形成速率和峰值凝块浊度降低,但与抗凝剂比较测量仅中度相关。在存在重组血栓调节蛋白的情况下,凝块溶解时间与 DOAC 浓度呈反比关系。通过浊度测量血浆凝块形成和溶解,可直接在体外比较不同类别的抗凝剂的作用。抗凝剂以 DOAC 的血浆浓度方式抑制凝块形成,依赖于 INR 的苯丙香豆素,和抗 Xa 的 LMWH。纤溶敏感性随 DOAC 浓度的增加而增加。